Novel Interventions for Colorectal Cancer
(CANTOR Trial)

Recruiting in Palo Alto (17 mi)

+49 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Recruiting

Sponsor: AstraZeneca

No Placebo Group

Prior Safety Data

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?

The main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC).

Research Team

Eligibility Criteria

This trial is for adults with confirmed colorectal cancer, good performance status (able to carry out daily activities), expected to live at least 12 weeks, no liver metastasis, and haven't had systemic therapy for metastatic CRC. They must have a specific tumor type (pMMR/MSS), be over 35 kg in weight, and have measurable disease.

Inclusion Criteria

My doctor expects me to live for at least 12 more weeks.

My diagnosis is colorectal adenocarcinoma confirmed by tissue analysis.

I can provide a tumor sample that was collected according to standard procedures.

See 7 more

Treatment Details

Interventions

Bevacizumab (Monoclonal Antibodies)
FOLFIRI (Anti-metabolites)
Volrustomig (Other)

Trial OverviewThe study tests the safety and effectiveness of new treatments and combinations in colorectal cancer patients. It includes Bevacizumab, Volrustomig, and FOLFIRI regimen which consists of Fluorouracil (5-FU), leucovorin, and irinotecan.

Participant Groups

2Treatment groups

Experimental Treatment

Active Control

Group I: Volrustomig + FOLFIRI+ Bevacizumab group (Arm A)Experimental Treatment3 Interventions

Participants will receive FOLFIRI and bevacizumab together with volrustomig.

Group II: FOLFIRI+ BEVACIZUMAB group (Arm B)Active Control2 Interventions

Partcipants will receive FOLFIRI and bevacizumab.